Olezarsen Trial Success: Recent chatter on X about Ionis Pharmaceuticals has centered on the positive Phase 3 trial results for Olezarsen, a drug showing significant reductions in triglycerides and pancreatitis events. Many are excited about its potential as a blockbuster, with discussions pointing to analyst upgrades and increased price targets. This has fueled a notable surge in the stock’s visibility online.
Regulatory and Financial Moves: Alongside trial data, X posts have highlighted a favorable regulatory opinion in Europe for DAWNZERA, aimed at preventing hereditary angioedema attacks. There’s also talk of a recent $770 million convertible notes offering, seen by some as a strategic financial step. A director’s multi-million dollar stock sale has sparked mixed reactions among followers.
Pipeline Expectations: Conversations on X also touch on upcoming Phase 3 results expected over the next year for other Ionis drugs, adding to the anticipation. Some express confidence in the company’s RNA-based therapy approach, viewing it as a leader in the biotech space. The buzz reflects high expectations for future developments.
Note: This discussion summary was generated from an AI condensation of post data.
Ionis Pharmaceuticals Insider Trading Activity
Ionis Pharmaceuticals insiders have traded $IONS stock on the open market 79 times in the past 6 months. Of those trades, 0 have been purchases and 79 have been sales.
Here’s a breakdown of recent trading of $IONS stock by insiders over the last 6 months:
- RICHARD S GEARY (EVP, Chief Development Officer) has made 0 purchases and 12 sales selling 203,468 shares for an estimated $14,161,179.
- PATRICK R. O'NEIL (EVP CLO & General Counsel) has made 0 purchases and 12 sales selling 216,005 shares for an estimated $13,811,605.
- BRETT P MONIA (Chief Executive Officer) has made 0 purchases and 6 sales selling 207,843 shares for an estimated $12,482,827.
- JOSEPH H WENDER has made 0 purchases and 11 sales selling 100,800 shares for an estimated $6,397,273.
- JOSEPH BAROLDI (EVP, Chief Business Officer) has made 0 purchases and 6 sales selling 61,625 shares for an estimated $3,837,493.
- JOSEPH III KLEIN has made 0 purchases and 2 sales selling 56,000 shares for an estimated $3,360,000.
- ELIZABETH L HOUGEN (EVP, Finance & CFO) sold 49,800 shares for an estimated $3,249,733
- JOAN E HERMAN has made 0 purchases and 2 sales selling 44,000 shares for an estimated $3,173,830.
- C FRANK BENNETT (EVP, Chief Scientific Officer) has made 0 purchases and 4 sales selling 54,909 shares for an estimated $3,098,620.
- ERIC SWAYZE (EVP Research) has made 0 purchases and 6 sales selling 45,146 shares for an estimated $2,823,225.
- BRIAN BIRCHLER (EVP, Corp and Development Ops) has made 0 purchases and 3 sales selling 31,900 shares for an estimated $2,333,366.
- JOSEPH LOSCALZO has made 0 purchases and 2 sales selling 32,000 shares for an estimated $2,164,040.
- EUGENE SCHNEIDER (EVP, Chf Clinical Develop Ofcr) has made 0 purchases and 3 sales selling 29,207 shares for an estimated $1,604,121.
- B LYNNE PARSHALL has made 0 purchases and 5 sales selling 30,000 shares for an estimated $1,586,665.
- SHANNON L. DEVERS (EVP, Chief Human Resources Ofc) has made 0 purchases and 3 sales selling 10,425 shares for an estimated $723,580.
- ALLENE M. DIAZ sold 1,427 shares for an estimated $60,687
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Ionis Pharmaceuticals Hedge Fund Activity
We have seen 248 institutional investors add shares of Ionis Pharmaceuticals stock to their portfolio, and 198 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 2,891,792 shares (-18.0%) from their portfolio in Q3 2025, for an estimated $189,181,032
- ORBIMED ADVISORS LLC removed 2,540,136 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $100,360,773
- ADAGE CAPITAL PARTNERS GP, L.L.C. removed 2,485,000 shares (-65.4%) from their portfolio in Q3 2025, for an estimated $162,568,700
- DEERFIELD MANAGEMENT COMPANY, L.P. added 1,979,669 shares (+inf%) to their portfolio in Q3 2025, for an estimated $129,509,945
- BVF INC/IL removed 1,913,385 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $125,173,646
- MILLENNIUM MANAGEMENT LLC removed 1,869,957 shares (-70.6%) from their portfolio in Q3 2025, for an estimated $122,332,586
- BELLEVUE GROUP AG removed 1,608,747 shares (-20.5%) from their portfolio in Q3 2025, for an estimated $105,244,228
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Ionis Pharmaceuticals Analyst Ratings
Wall Street analysts have issued reports on $IONS in the last several months. We have seen 12 firms issue buy ratings on the stock, and 1 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 11/10/2025
- Piper Sandler issued a "Overweight" rating on 11/04/2025
- Barclays issued a "Overweight" rating on 10/30/2025
- Needham issued a "Buy" rating on 10/30/2025
- Raymond James issued a "Strong Buy" rating on 10/30/2025
- Morgan Stanley issued a "Overweight" rating on 10/30/2025
- TD Cowen issued a "Buy" rating on 10/30/2025
To track analyst ratings and price targets for Ionis Pharmaceuticals, check out Quiver Quantitative's $IONS forecast page.
Ionis Pharmaceuticals Price Targets
Multiple analysts have issued price targets for $IONS recently. We have seen 20 analysts offer price targets for $IONS in the last 6 months, with a median target of $83.5.
Here are some recent targets:
- Mitchell S. Kapoor from HC Wainwright & Co. set a target price of $110.0 on 11/10/2025
- Allison Bratzel from Piper Sandler set a target price of $77.0 on 11/04/2025
- Gena Wang from Barclays set a target price of $95.0 on 10/30/2025
- Michael Ulz from Morgan Stanley set a target price of $94.0 on 10/30/2025
- Yaron Werber from TD Cowen set a target price of $99.0 on 10/30/2025
- Luca Issi from RBC Capital set a target price of $82.0 on 10/30/2025
- Joseph Stringer from Needham set a target price of $90.0 on 10/30/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
